Page 1 | Search Results | Blood | American Society of Hematology

1-10 of 10

Sort by

Sort Order Select

Journal Articles

NGS better discriminates true MRD positivity for the risk stratification of childhood ALL treated on an MRD-based protocol

Michael Svaton, Aneta Skotnicova, Leona Reznickova, Andrea Rennerova, Tatana Valova, Michaela Kotrova, Vincent H. J. van der Velden, Monika Brüggemann, Nikos Darzentas, Anton W. Langerak, Jan Zuna, Jan Stary, Jan Trka, Eva Fronkova

Blood (2023) 141 (5): 529–533.

https://doi.org/10.1182/blood.2022017003

Published: 2023

Includes: Supplemental data

Journal Articles

NGS-Based MRD Quantitation: An Alternative to qPCR Validated on a Large Consecutive Cohort of Children with ALL

Michael Svaton, Aneta Skotnicova, Leona Reznickova, Andrea Rennerova, Tatana Valova, Michaela Kotrova, Vincent H.J. van der Velden, Monika Brüggemann, Nikos Darzentas, Anton W. Langerak, Jan Zuna, Jan Stary, Jan Trka, Eva Fronkova

Blood (2021) 138 (Supplement 1): 1314.

https://doi.org/10.1182/blood-2021-152971

Published: 2021

Journal Articles

Epigenetic Changes in CEBPα Gene and Xenotransplantation Model of B Cell Precursor Acute Lymphoblastic Leukemia Switching to Monocytoid Lineage During the Early Phase of the Treatment

Blood (2012) 120 (21): 876.

https://doi.org/10.1182/blood.V120.21.876.876

Published: 2012

Journal Articles

Prognostic Impact of Peripheral Blood Involvement during Early Time Points of Childhood ALL Treatment.

Jana Volejnikova, MD, Eva Fronkova, MD, PhD, Ester Mejstrikova, MD, Katerina Muzikova, Leona Reznickova, Dagmar Pospisilova, MD, Jaroslav Sterba, MD, PhD, Yahia Jabali, MD, Daniela Prochazkova, MD, Bohumir Blazek, MD, Jiri Hak, MD, Zdenka Cerna, MD, Jan Stary, MD, PhD, Jan Trka, MD, PhD

Blood (2008) 112 (11): 1489.

https://doi.org/10.1182/blood.V112.11.1489.1489

Published: 2008

Journal Articles

MRD Monitoring Reveals a Specific Biology of BCR/ABL-Positive ALL

Marketa Zaliova, Leona Reznickova, Eva Fronkova, Katerina Krejcikova, Katerina Muzikova, Claus Meyer, Rolf Marschalek, Jan Stary, Jan Trka, Jan Zuna

Blood (2008) 112 (11): 2529.

https://doi.org/10.1182/blood.V112.11.2529.2529

Published: 2008

Journal Articles

Biology of Childhood Acute Hybrid Leukemias in a Population-Based Study (Czech Pediatric Hematology Working Group).

Ester Mejstrikova, MD, Jana Volejnikova, Eva Fronkova, Tomas Kalina, Katerina Zdrahalova, Andrea Polouckova, Elena Vodickova, Zuzana Zemanova, Leona Reznickova, Martina Vaskova, Martin Kovac, Jan Zuna, Jan Trka, Jan Stary, Ondrej Hrusak

Blood (2007) 110 (11): 4247.

https://doi.org/10.1182/blood.V110.11.4247.4247

Published: 2007

Journal Articles

Limited Reliability of Ig/TCR Based MRD Monitoring in BCR/ABL-Positive Childhood ALL: Comparison to Quantitative Fusion Transcript Detection.

Katerina Krejcikova, Katerina Muzikova, Eva Fronkova, Marketa Kalinova, Leona Reznickova, Jan Zuna, Jan Stary, Jan Trka

Blood (2006) 108 (11): 2340.

https://doi.org/10.1182/blood.V108.11.2340.2340

Published: 2006

Journal Articles

Minimal Residual Disease (MRD) Analysis in Non-MRD Based ALL IC-BFM 2002 Protocol for Childhood ALL: Is It Possible To Omit Minimal Residual Disease in Risk Stratification?.

Eva Fronkova, Smadar Avigad, Ki Wai Chik, Luis Castillo, Manor Sigal, Leona Reznickova, Katerina Zdrahalova, Tatana Skocovska, Martin Schrappe, Valentino Conter, Shai Izraeli, Chi Kong Li, Batia Stark, Ondrej Hrusak, Ester Mejstrikova, Jan Stary, Jan Trka

Blood (2006) 108 (11): 2271.

https://doi.org/10.1182/blood.V108.11.2271.2271

Published: 2006

Journal Articles

Detectable Minimal Residual Disease before Haematopoietic Stem Cell Transplantation Predicts Extremely Poor Prognosis in Children with Acute Lymphoblastic Leukaemia.

Katerina Muzikova, Bc, Eva Fronkova, MD, Lucie Sramkova, MD, Leona Reznickova, Renata Formankova, MD, PhD, Petr Sedlacek, MD, CSc, Jan Stary, MD, DrSc, Jan Trka, MD, PhD

Blood (2005) 106 (11): 2037.

https://doi.org/10.1182/blood.V106.11.2037.2037

Published: 2005

Journal Articles

Minimal Residual Disease Detection Identifies Differences between the Risk Groups Defined by the ALL IC-BFM 2002 and the ALL-BFM 2000 Protocols.

Eva Fronkova, MD, Leona Reznickova, Katerina Muzikova, Ester Mejstrikova, MD, Ondrej Hrusak, MD, PhD, Martin Schrappe, MD, PhD, Jan Stary, MD, PhD, Jan Trka, MD, PhD

Blood (2004) 104 (11): 1085.

https://doi.org/10.1182/blood.V104.11.1085.1085

Published: 2004

NARROW

NGS better discriminates true MRD positivity for the risk stratification of childhood ALL treated on an MRD-based protocol

NGS-Based MRD Quantitation: An Alternative to qPCR Validated on a Large Consecutive Cohort of Children with ALL

Epigenetic Changes in CEBPα Gene and Xenotransplantation Model of B Cell Precursor Acute Lymphoblastic Leukemia Switching to Monocytoid Lineage During the Early Phase of the Treatment

Prognostic Impact of Peripheral Blood Involvement during Early Time Points of Childhood ALL Treatment.

MRD Monitoring Reveals a Specific Biology of BCR/ABL-Positive ALL

Biology of Childhood Acute Hybrid Leukemias in a Population-Based Study (Czech Pediatric Hematology Working Group).

Limited Reliability of Ig/TCR Based MRD Monitoring in BCR/ABL-Positive Childhood ALL: Comparison to Quantitative Fusion Transcript Detection.

Minimal Residual Disease (MRD) Analysis in Non-MRD Based ALL IC-BFM 2002 Protocol for Childhood ALL: Is It Possible To Omit Minimal Residual Disease in Risk Stratification?.

Detectable Minimal Residual Disease before Haematopoietic Stem Cell Transplantation Predicts Extremely Poor Prognosis in Children with Acute Lymphoblastic Leukaemia.

Minimal Residual Disease Detection Identifies Differences between the Risk Groups Defined by the ALL IC-BFM 2002 and the ALL-BFM 2000 Protocols.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only